In china, previous studies showed patients with non-Hodgkin lymphoma (NHL) are likely to have hepatitis B virus (HBV) infection. The risk of HBV reactivation is high when patients were treated with CHOP, especially in combination with rituximab. The aim of this study is to compare entecavir with lamivudine, 2 commonly used anti-virus agents, for preventing the risk of HBV reactivation in patients with NHL on CHOP/R-CHOP.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Previously untreated NHL suitable for CHOP/R-CHOP treatment
Age range 18-80 years old
HBsAg positive with high level of HBV DNA
Eastern Cooperative Oncology Group performance status 0-2
Life expectancy of more than 3 months
Adequate organ function
You may not be if
Primary or secondary central nervous system involvement
With hepatitis C virus infection
Previous serious cardiac disease
History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
Pregnant or lactating women
Serious uncontrolled diseases and intercurrent infection